Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Translational Lung Cancer Research|October 17, 2022
Efficacy and safety of amrubicin therapy after chemoimmunotherapy in small cell lung cancer patientsKohei Kushiro, Satoshi Watanabe, Yuka Goto, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 5, 2015
Critical Roles of Chemoresistant Effector and Regulatory T Cells in Antitumor Immunity after Lymphodepleting ChemotherapyYu Saida, Satoshi Watanabe, Tomohiro Tanaka, et al.
Thoracic Cancer|September 12, 2019
Efficacy of EGFR-TKIs with or without upfront brain radiotherapy for EGFR-mutant NSCLC patients with central nervous system metastasesYu Saida, Satoshi Watanabe, Tetsuya Abe, et al.
Cancer Immunology, Immunotherapy : CII|October 17, 2021
PD-1 blockade therapy augments the antitumor effects of lymphodepletion and adoptive T cell transferMiho Takahashi, Satoshi Watanabe, Ryo Suzuki, et al.
Translational Lung Cancer Research|August 12, 2022
Phase II study of nanoparticle albumin-bound paclitaxel monotherapy for relapsed non-small cell lung cancer with patient-reported outcomes (NLCTG1302)Satoshi Shoji, Satoru Miura, Satoshi Watanabe, et al.
Plos One|August 31, 2017
Transfer of in vitro-expanded naïve T cells after lymphodepletion enhances antitumor immunity through the induction of polyclonal antitumor effector T cellsTomohiro Tanaka, Satoshi Watanabe, Miho Takahashi, et al.
Scientific Reports|June 10, 2021
Real-Time insight into in vivo redox status utilizing hyperpolarized [1-<sup>13</sup>C] N-acetyl cysteineKazutoshi Yamamoto, Ana Opina, Deepak Sail, et al.
Scientific Reports|May 6, 2026
Muscle loss and pentraxin-3 as predictors of immunotherapy outcomes in non-small cell lung cancer: a prospective studyTakaaki Masuda, Satoshi Watanabe, Ryo Suzuki, et al.
Cancer Immunology, Immunotherapy : CII|March 5, 2026
Nintedanib enhances the antitumor efficacy of pd-1 blockade, potentially through inhibition of myeloid-derived suppressor cells and cancer-associated fibroblastsRyo Suzuki, Satoshi Watanabe, Kunihiro Shono, et al.
Cancers|January 8, 2023
Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory <i>ALK</i>-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501)Satoshi Watanabe, Kazuko Sakai, Naoya Matsumoto, et al.
Pageof 3